✦ LIBER ✦
Switching cholinesterase inhibitor therapy in Alzheimer's disease—donepezil to rivastigmine, is it worth it?
✍ Scribed by Roger Bullock; Claire Connolly
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 34 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-6230
- DOI
- 10.1002/gps.542
No coin nor oath required. For personal study only.
✦ Synopsis
Switching from donepezil to rivastigmine was bene®cial in cognitive and global terms in 55.0% of the patients with Alzheimer's disease studied. * Side-effects on donepezil and rivastigmine were independent of one another. * It may be possible to extend the positive effects that cholinesterase inhibitors offer by switching drugs if the initial drug cannot be tolerated or does not produce the required effect. * Research is needed to determine good clinical practice with regard to switching drug therapy in the treatment of Alzheimer's disease.